Editas Medicine, Inc.

What they do

Editas develops CRISPR-based gene editing medicines, using its proprietary platform that includes Cas9 and Cas12a enzymes. Its current focus is in vivo functional upregulation, editing non-coding regulatory sequences to increase expression of normal genes. The lead program, EDIT-401, aims to reduce LDL cholesterol by upregulating the LDL receptor, targeting heterozygous familial hypercholesterolemia. The company also has a preclinical 'plug and play' lipid nanoparticle platform for targeted delivery to liver and other tissues.

Revenue drivers

• Collaboration and other research and development revenues — Primarily from collaborations with partners like BMS; revenue recognized when performance obligations are satisfied or when certain rights expire (e.g., deferred revenue recognized related to BMS opt-in expiration in Q2 2026).

Recent performance

For Q2 2026, Editas reported net loss of $18.2 million, or $0.15 per share, compared to a net loss of $53.2 million, or $0.63 per share, in Q2 2025. Collaboration and other R&D revenues increased to $11.9 million in Q2 2026 from $3.6 million in Q2 2025. Quarterly revenue fluctuated: $7.5M (Sep 2025), $24.7M (Dec 2025), $2.8M (Mar 2026), $11.9M (Jun 2026). Cash and cash equivalents were $211.6 million as of June 30, 2026, up from $146.6 million at year-end 2025. The company reported shareholder equity of $105.3 million and long-term debt of $48.2 million as of June 30, 2026.

Strategy

Editas is concentrating on in vivo gene editing, specifically functional upregulation, to treat diseases where knockdown or correction approaches are limited. The company aims to build a pipeline around EDIT-401, with a focus on best-in-class, one-time therapies that simplify patient administration and manufacturing. It is developing a 'plug and play' LNP delivery platform to expand addressable tissues beyond the liver. Management plans to advance EDIT-401 into clinical trials, with a CTN submission in Australia and a Phase 1/2 study in HeFH patients. Recent equity financing of $125.0 million gross proceeds strengthens the balance sheet to support this pipeline.

Risks

• Clinical and regulatory uncertainty — EDIT-401 is still in preclinical development; failure to commence or complete clinical trials could substantially harm the business.
• History of losses — The company has incurred significant losses since inception and expects to continue losing money, with no product sales revenue.
• Need for additional funding — While cash runway extends into H2 2028, the company will require substantial additional capital to advance EDIT-401 and other programs if milestones slip.
• New technology risk — Gene editing regulatory requirements are evolving, and the field is relatively new, which could lead to delays or unexpected hurdles.

Outlook

Management expects to submit a Clinical Trial Notification (CTN) in Australia in August 2026 and initiate a Phase 1/2 trial of EDIT-401 in HeFH patients. A data update is expected in Q1 2027, with topline results from Part 1 (dose-finding) anticipated in 2027. The company is funded into the second half of 2028.